Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Estrogen-receptor Positive Breast Cancer”

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00856492
What this trial is testing

S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer

Who this might be right for
Breast Cancer
SWOG Cancer Research Network 215
Early research (Phase 1)Study completedNCT04647487
What this trial is testing

LY3484356 in Women With Breast Cancer Before Having Surgery

Who this might be right for
Breast Cancer
Eli Lilly and Company 87
Very early researchLooking for participantsNCT05659797
What this trial is testing

FES BPET-DBT in Newly Diagnosed Breast Cancer

Who this might be right for
Breast Cancer
Abramson Cancer Center at Penn Medicine 20
Large-scale testing (Phase 3)UnknownNCT00541086
What this trial is testing

Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery

Who this might be right for
Breast Cancer
Gruppo Italiano Mammella (GIM) 3,697
Testing effectiveness (Phase 2)Ended earlyNCT02395627
What this trial is testing

Reversing Therapy Resistance With Epigenetic-Immune Modification

Who this might be right for
Breast Neoplasms
University of California, San Francisco 38
Testing effectiveness (Phase 2)Active Not RecruitingNCT05296746
What this trial is testing

Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer

Who this might be right for
Breast Cancer Stage II
SOLTI Breast Cancer Research Group 1,100
Large-scale testing (Phase 3)UnknownNCT03351062
What this trial is testing

Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer

Who this might be right for
Breast Cancer Female
Chinese Anti-Cancer Association 844
Large-scale testing (Phase 3)Ended earlyNCT03439046
What this trial is testing

Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 287
Not applicableUnknownNCT02088710
What this trial is testing

Expectations and Side Effects of Endocrine Therapy in Women With Breast Cancer

Who this might be right for
Female Breast Cancer
Philipps University Marburg 138
Large-scale testing (Phase 3)Study completedNCT01626222
What this trial is testing

4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals 301
Testing effectiveness (Phase 2)Looking for participantsNCT06167694
What this trial is testing

Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer

Who this might be right for
Unresectable or Metastatic Breast Cancer
Shandong Suncadia Medicine Co., Ltd. 146
Testing effectiveness (Phase 2)Looking for participantsNCT06450873
What this trial is testing

Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery

Who this might be right for
Estrogen Receptor-Positive Breast CarcinomaHER2-Negative Breast Carcinoma
Mayo Clinic 40
Early research (Phase 1)Ended earlyNCT03816839
What this trial is testing

Evaluation of Orally Administered Amcenestrant (SAR439859) in Japanese Postmenopausal Patients With Advanced Breast Cancer (AMEERA-2)

Who this might be right for
Breast Cancer
Sanofi 10
Not applicableStudy completedNCT01298362
What this trial is testing

Impact of Chemotherapy Followed by Aromatase Inhibitors on Bone Health of Women With ER-positive Early Breast Cancer

Who this might be right for
Breast CancerOther Disorders of Bone Density and Structure
Hellenic Breast Surgeons Society 290
Testing effectiveness (Phase 2)Ended earlyNCT01230970
What this trial is testing

Exploratory Study to Assess the Short Term Intratumoural and Peripheral Effects of BN83495 in Postmenopausal Women With Newly Diagnosed Breast Cancer

Who this might be right for
Breast Cancer
Ipsen 2
Testing effectiveness (Phase 2)Looking for participantsNCT07427394
What this trial is testing

Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
AstraZeneca 24
Early research (Phase 1)Study completedNCT03916744
What this trial is testing

Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer

Who this might be right for
Breast Cancer
Genentech, Inc. 75
Not applicableStudy completedNCT03726931
What this trial is testing

FES (16α-[18F]-Fluoro-17β-estradiol)-PET: Towards a New Standard to Stage Locally Advanced and Recurrent, Estrogen Receptor Positive (ER+) Breast Cancer? Pilot Study to Compare [18F]FES-PET and [18F]FDG-PET

Who this might be right for
Breast Cancer
Amsterdam UMC, location VUmc 40
Not applicableStudy completedNCT00965939
What this trial is testing

An Observational Study to Assess Response to Tamoxifen in Breast Cancer Patients

Who this might be right for
ER-positive Breast Cancer
Vlaamse Vereniging voor Obstetrie en Gynaecologie 300
Testing effectiveness (Phase 2)Looking for participantsNCT06953882
What this trial is testing

Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy

Who this might be right for
HER2 Negative Breast Cancer
Yale University 140
Next Page

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation